For example, in the GSE9782 trial, myeloma patients (n = 265 total) in the top quartile of CDCA7L expression (measured in bone marrow plasma cells) exhibited significantly shorter overall survival than patients in the bottom quartile [p = 3.1 × 10-4; hazard ratio (HR) = 2.3]. The gene discussed is CDCA7L; the disease is plasma cell myeloma.